Novartis AG Sponsored ADR (NVS)
Novartis AG (NVS) Q1 2025 Earnings Call Transcript
Novartis AG (NYSE:NVS ) Q1 2025 Earnings Conference Call April 29, 2025 8:00 AM ET Company Participants Sloan Simpson - Head of Investor Relations Vas Narasimhan - CEO Harry Kirsch - CFO Conference Call Participants Simon Baker - Redburn Atlantic Graham Parry - Bank of America Emmanuel Papadakis - Deutsche Bank Florent Cespedes - Bernstein Peter Verdult - BNP Paribas Exane Richard Vosser - JPMorgan James Quigley - Goldman Sachs Thibault Boutherin - Morgan Stanley Matthew Weston - UBS Kerry Holford - Berenberg Seamus Fernandez - Guggenheim Steve Scala - TD Securities Operator Good morning and good afternoon, and welcome to the Novartis Q1 2025 Results Release Conference Call and Live Webcast. [Operator Instructions] A recording of the conference call, including the Q&A session, will be available on our website shortly after the call ends.
Compared to Estimates, Novartis (NVS) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Novartis Beats on Q1 Earnings and Sales, Raises Guidance, Stock Up
NVS' first-quarter earnings and sales beat estimates. Based on the strong momentum of its key drugs, the company raises its annual guidance.
Novartis Lifts Guidance After Profit, Sales Top Views
Novartis raised its 2025 outlook after its core operating profit rose 23% on year, boosted by strong demand for its key drugs.
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Novartis and Sanofi CEOs say EU should raise drug prices in face of tariffs
The European Union should allow drug prices to rise to U.S. levels in order to attract investment, the bosses of two European pharmaceutical giants said in a letter published in the Financial Times on Wednesday.
Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum?
NVS' first-quarter performance has likely benefited from strong growth in Kisqali, Kesimpta, Pluvicto, Leqvio, Scemblix and Fabhalta.
Why Novartis (NVS) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes?
NVS Plans to Invest $23B in US Manufacturing Sites Amid Tariff Threat
Novartis plans to expand its current manufacturing, research and technology presence in the United States following Trump's announcement of tariffs on pharmaceutical imports.
Novartis Plans $23B Investment in US Facilities as Trump Threatens Pharma Tariffs
Swiss pharmaceutical giant Novartis (NVS) said it plans to invest $23 billion in the construction and expansion of 10 U.S. facilities, as drugmakers brace for potential tariffs from the Trump administration.
Novartis plans to invest $23 billion in US plants as Trump renews drug tariff threats
Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 facilities in the U.S., as it grapples with renewed threats of drug import duties from the Trump administration.
Novartis After Sandoz: The Business Without Generics
Novartis has restructured to focus solely on innovative branded drugs, showing double-digit growth in revenue and profit in 2024. The company is strong in oncology, cardiology, immunology, and neurology, with key drugs like Entresto, Cosentyx, Kisqali, and Pluvicto driving growth. Novartis plans to grow by 5% annually, aiming for a 40% operating margin and up to 20 new molecule approvals by 2030.
